Benign thyroid tumors comprise a heterogeneous group of neoplastic and tumor-like lesions with nonmetastatic behavior that arise predominantly from follicular cells and, less commonly, from the stromal, vascular, or neural components of the gland. In clinical practice, the term is often used broadly to include the more common non-neoplastic nodular lesions because the clinical objective is the same: to distinguish conditions without biological aggressiveness from malignant neoplasms and to determine when a lesion requires treatment because of symptoms, hyperfunction, or procedural risk. This condition must be considered within the context of the high prevalence of thyroid nodules in the general population, in which the vast majority of lesions are benign.
From a biological perspective, the main benign follicular neoplasms are follicular adenoma and its oncocytic variants, which are generally characterized by slow, encapsulated growth and by the absence of histological criteria of malignancy, particularly capsular and vascular invasion. Alongside these entities, benign nodular thyroid disease includes hyperplastic nodules and areas of functional autonomy, which may cause hyperthyroidism when supported by constitutive activation of the thyroid-stimulating hormone pathway, with clinically significant systemic consequences despite the absence of oncological aggressiveness. The thyroid may also harbor rare benign lesions of mesenchymal or vascular origin, which are generally described only in limited case series.
Diagnostic assessment requires a systematic approach integrating medical history, physical examination, hormonal functional assessment, and ultrasound-based risk stratification, with fine-needle aspiration when indicated for cytological characterization. Therapeutic management ranges from clinical and ultrasound surveillance to surgery and image-guided minimally invasive options in selected cases, with the aim of controlling compressive symptoms, preventing complications, and treating functional autonomy when present. In most cases, the prognosis is excellent, and quality of life depends primarily on the appropriate choice between surveillance and intervention, avoiding unnecessary procedures and minimizing functional sequelae.
The epidemiology of benign thyroid tumors largely overlaps with that of thyroid nodular disease, since many clinically relevant lesions present as palpable nodules or incidental findings. Thyroid nodules are extremely common: ultrasound studies in the general population show a broad prevalence that increases with age and is higher among women. In most patients, thyroid nodules are benign, and their clinical relevance derives mainly from the need to exclude thyroid carcinoma and identify functionally autonomous lesions that may cause thyrotoxicosis.
Among benign follicular neoplasms, follicular adenoma is a typical diagnosis in patients with a solitary, solid, well-circumscribed nodule, often detected in adulthood. Its sex distribution generally follows that of thyroid nodularity as a whole, with a higher prevalence among women. Oncocytic variants may present as solid nodules at a more advanced age than other follicular lesions, and their clinical behavior is determined primarily by nodule volume and cosmetic or compressive effects rather than by an aggressive biological risk when histological criteria confirm benignity.
Risk factors for benign thyroid nodularity include iodine deficiency and chronic stimulation of thyroid tissue, which promote hyperplasia and nodule formation. In areas with low iodine availability, nodular thyroid disease and functional autonomy are more frequent, and hyperthyroidism caused by an autonomous nodule or toxic multinodular goiter represents a clinically relevant phenotype. Exposure to ionizing radiation involving the head and neck also increases the likelihood of developing thyroid nodules over time, although clinical attention in these patients is primarily directed toward their overall neoplastic risk and the appropriate selection of diagnostic investigations.
Additional epidemiological determinants include a family history of nodular thyroid disease, chronic autoimmune thyroiditis, obesity, and associated metabolic factors, which have been correlated with a higher prevalence of nodules in the population, although causal relationships are not always consistent. In this context, hormonal status, particularly the thyroid-stimulating hormone level, influences nodule growth and dynamics even when values remain within the reference range. A relatively higher thyroid-stimulating hormone level is associated with a greater probability of clinically relevant nodules, whereas functional autonomy is often associated with suppressed thyroid-stimulating hormone levels.
For rare benign tumors of nonfollicular origin, such as certain intrathyroidal vascular or neural lesions, no clearly defined risk factors exist because the literature consists mainly of isolated reports and small case series. In clinical practice, the most relevant factor affecting clinical impact remains the size of the nodule and its anatomical relationship with the trachea and esophagus, since these features determine compressive symptoms and may lead to treatment even in the complete absence of oncological suspicion.
Population screening programs are not indicated for benign thyroid tumors. The high prevalence of thyroid nodules in the general population, combined with the fact that most are benign and often clinically irrelevant, creates a risk of overdiagnosis and unnecessary diagnostic pathways if systematic investigations are performed in asymptomatic individuals. Consequently, thyroid nodules are typically identified in two settings: as incidental findings during ultrasound examinations performed for other reasons, or during targeted assessment prompted by symptoms, a palpable goiter, or abnormalities of thyroid function.
Surveillance is primarily applied to nodular lesions considered to be at low risk after clinical, ultrasound, and, when indicated, cytological assessment. Within this approach, the key factor is not simply the presence of a nodule, but the consistency among its ultrasound morphology, the clinical context, and the results of fine-needle aspiration when performed. A nodule with benign cytology and nonsuspicious ultrasound characteristics may be monitored through clinical and ultrasound follow-up, with the frequency of examinations adjusted according to the ultrasound risk profile and stability over time.
Surveillance should not be understood as the automatic repetition of procedures, but as rational monitoring intended to detect clinically significant events, including the onset of compressive symptoms, substantial changes in ultrasound appearance, the development of suspicious lymphadenopathy, or progression of functional autonomy. An increase in volume alone is not a reliable indicator of malignant transformation in a nodule with benign cytology and must be interpreted in the context of ultrasound findings and the adequacy of the cytological specimen.
The surveillance of functionally autonomous lesions requires specific consideration. When the thyroid-stimulating hormone level is reduced, the assessment strategy includes thyroid scintigraphy to determine whether a hyperfunctioning nodule is present and to evaluate its contribution to hormone production. In these cases, surveillance is primarily aimed at preventing complications of subclinical or overt hyperthyroidism, such as atrial fibrillation and loss of bone mass, and at determining the appropriate timing of definitive treatment, which may involve radioactive iodine, surgery, or, in selected cases, image-guided thermal ablation.
After treatment of a benign nodule, surveillance depends on the technique used. Following surgery, follow-up focuses on the assessment of thyroid function and treatment-related sequelae, as well as on the possible development of nodules in the remaining thyroid parenchyma after partial resection. After minimally invasive ablation, ultrasound examinations are intended to document volume reduction, stability of the treated area, and the absence of clinically relevant regrowth, together with functional assessment in patients with autonomous nodules or those at risk of postprocedural hypothyroidism.
The biology of benign thyroid tumors reflects the heterogeneity of their cells of origin and of the pathogenetic mechanisms that lead to nodule formation. In most cases, the clinical phenotype is that of a well-demarcated, often encapsulated nodule that grows slowly within the thyroid parenchyma. This behavior results from generally well-differentiated cellular proliferation, with an orderly architecture and absence of the morphological features that define malignancy in follicular neoplasms, particularly capsular and vascular invasion.
A degree of morphological and biological overlap exists within the continuum between non-neoplastic nodularity and follicular adenoma. Benign nodular thyroid disease may be supported by polyclonal hyperplasia related to trophic stimuli, such as iodine deficiency and thyroid-stimulating hormone stimulation, but a proportion of nodules show clonal characteristics and molecular alterations suggesting a neoplastic origin or progression toward proliferative autonomy. This explains why some hyperplastic nodules and some adenomas share ultrasound and cytological features and why definitive distinction often requires histological assessment of the excised nodule.
A pathogenetic mechanism of major clinical relevance is functional autonomy. Autonomous nodules are driven by constitutive activation of the thyroid-stimulating hormone receptor pathway and the cyclic adenosine monophosphate cascade, resulting in hormone production that is independent of pituitary regulation. Activating somatic mutations of TSHR and, less frequently, GNAS are well documented in series of toxic adenomas and provide the biological rationale for scintigraphy as an assessment of physiology as well as an imaging examination. In settings of iodine deficiency, autonomy may emerge more readily and contribute to nodular hyperthyroidism.
With regard to the genetics of follicular lesions, alterations in genes of the RAS pathway may be detected across a broad spectrum that includes benign nodules and follicular adenomas, suggesting that these events may create a biological environment favorable to follicular proliferation without being synonymous with malignancy. Progression to carcinoma typically requires additional genetic and microenvironmental events, which is why the detection of certain molecular alterations alone does not define clinical behavior without correlation with morphology and histological criteria.
Oncocytic variants, often described as oncocytic nodules or oncocytic adenomas when benign, exhibit a cellular phenotype characterized by granular eosinophilic cytoplasm rich in mitochondria. Numerous studies have associated this phenotype with alterations of the mitochondrial genome and cellular bioenergetics, with disruptive mutations in complex I subunits acting as markers of the oncocytic phenotype. In this setting as well, the distinction between oncocytic adenoma and oncocytic carcinoma depends on histological evidence of invasion rather than on cytology alone, which may yield an indeterminate result.
Histologically, follicular adenoma is typically a well-circumscribed, encapsulated lesion composed of follicles of variable size, without capsular or vascular invasion. The oncocytic variant consists of cells with abundant eosinophilic cytoplasm and a follicular or solid architecture, while retaining the criteria of benignity when invasion is absent. Other benign lesions, such as hyperplastic or degenerative nodules, may show areas of fibrosis, hemorrhage, and dystrophic calcification, which account for their variable ultrasound appearance and the frequent presence of cystic components.
Immunohistochemistry primarily has a supportive role in differential diagnosis, whereas the definition of benignity in follicular neoplasms remains a morphological determination based on the absence of invasiveness. Overall, the pathogenesis of benign thyroid tumors is dominated by interactions among trophic stimuli, clonal events, and, in specific subgroups, constitutive activation of signaling pathways that confer functional autonomy or distinctive cellular phenotypes, with direct implications for clinical presentation and therapeutic decisions.
The clinical manifestations of benign thyroid tumors depend primarily on the size, location, and function of the nodule, as well as on the presence of multinodular goiter. A substantial proportion of patients are asymptomatic and undergo evaluation because of an incidental ultrasound finding or a cervical swelling noticed by chance. When present, symptoms often develop slowly and reflect either a mass effect in the neck or altered thyroid function in autonomous lesions.
During history-taking, the patient may report a sensation of pressure or tightness in the neck, local discomfort, or awareness of a nodule. Compressive symptoms become more likely with large nodules, retrosternal goiter, or posterior growth. These patients may develop dysphagia for solid foods, a foreign-body sensation, difficulty swallowing tablets, or dyspnea, particularly when lying supine or during physical exertion. A persistent dry cough or frequent throat clearing may reflect local irritation or concomitant reflux, but warrants assessment when associated with increasing neck volume.
Dysphonia is a symptom that always requires attention because it may indicate involvement of the recurrent laryngeal nerve, although in benign conditions it is more commonly related to concomitant disorders or indirect compression in very large goiters. Acute local pain is relatively uncommon in stable benign tumors, but may occur in the presence of intranodular hemorrhage, necrosis, or rapid expansion of a cystic component, which can cause a sudden increase in volume and tenderness.
Functioning autonomous nodules produce a distinct clinical profile. In these patients, symptoms may be related to subclinical or overt hyperthyroidism and may include palpitations, heat intolerance, tremor, weight loss, anxiety, fatigue, and reduced exercise tolerance. In older adults, hyperthyroidism may present with more subtle manifestations and cardiovascular complications, including atrial fibrillation, making the prompt recognition of a suppressed thyroid-stimulating hormone level essential in patients with thyroid nodularity.
Physical examination assesses thyroid volume, consistency, mobility during swallowing, the presence of a solitary nodule or multinodularity, and signs of compression. Palpation may reveal a well-demarcated, elastic lesion or a firmer lesion when calcification or fibrosis is present. Examination of the lateral cervical lymph nodes is essential, not because benign tumors metastasize, but because the presence of suspicious lymphadenopathy radically changes the risk profile and requires a different diagnostic pathway. Voice assessment and, when indicated, otolaryngological examination complete the evaluation in patients with dysphonia or laryngeal symptoms.
Overall, the clinical presentation of benign thyroid tumors is dominated by three scenarios: an asymptomatic incidental finding, a compressive condition caused by nodule volume, and a functional condition caused by hormonal autonomy. This distinction guides the sequence of investigations and determines the threshold for intervention even when the oncological risk is low.
The diagnostic pathway for benign thyroid tumors begins by defining the clinical and functional context and continues with ultrasound-based morphological risk stratification, followed by cytological characterization when indicated. The rationale is twofold: to confirm that the lesion is compatible with benignity and, more importantly, to exclude a thyroid carcinoma that may present as a solitary nodule or as the dominant lesion within a multinodular goiter. The diagnostic process must also identify autonomous lesions, because treatment and systemic risks depend on thyroid function as well as on lesion size.
The initial laboratory assessment includes TSH, together with free thyroxine and free triiodothyronine when the thyroid-stimulating hormone level is reduced or when thyroid dysfunction is clinically suspected. A suppressed thyroid-stimulating hormone level suggests functional autonomy and changes the diagnostic algorithm, because thyroid scintigraphy can distinguish a hyperfunctioning nodule from nonfunctioning nodules in this setting. In euthyroid patients or those with normal thyroid-stimulating hormone levels, attention focuses on ultrasound risk stratification and the indication for fine-needle aspiration.
High-resolution thyroid ultrasound is the cornerstone examination. It should describe the location, three-dimensional measurements, composition, whether solid, cystic, or mixed, echogenicity, margins, calcifications, shape, and vascularity of the nodule, together with systematic evaluation of the lymph nodes in the central and lateral cervical compartments. Risk-stratification systems such as EU-TIRADS or the ultrasound categories proposed by international guidelines allow estimation of the probability of malignancy and definition of size thresholds for fine-needle aspiration, reducing unnecessary procedures in low-risk nodules and concentrating biopsies on lesions with suspicious characteristics.
When the thyroid-stimulating hormone level is low, scintigraphy with an appropriate radioisotope can identify hyperfunctioning nodules. The probability of malignancy in a hyperfunctioning nodule is generally lower than in a nonfunctioning nodule, and the clinical priority becomes the management of thyrotoxicosis and its complications. In nonfunctioning nodules or in euthyroid patients, the decision to perform fine-needle aspiration instead depends on the ultrasound risk profile and lesion size.
Ultrasound-guided fine-needle aspiration is the decisive investigation for many nodules and represents the principal tool for distinguishing benign nodules from suspicious lesions. Reporting according to the Bethesda System standardizes communication and associates each category with an estimated risk of malignancy and a recommended management strategy. The benign category typically includes colloid nodules, hyperplastic nodules, and thyroiditis and, when consistent with the clinical and ultrasound findings, supports a surveillance strategy.
A critical issue is the differential diagnosis of follicular neoplasms. Cytology may identify a follicular pattern but cannot reliably distinguish follicular adenoma from follicular carcinoma because this distinction requires histological demonstration of capsular or vascular invasion. Consequently, some nodules with indeterminate cytology are referred for diagnostic surgery or further risk-stratification strategies, which may include repeat fine-needle aspiration, expert ultrasound reassessment, and, in selected centers, molecular testing as a decision-support tool, always integrated with the clinical context.
The diagnostic assessment is completed with targeted investigations based on symptoms. In patients with large goiters or suspected retrosternal extension, computed tomography of the neck and mediastinum without iodinated contrast may be useful to define anatomical relationships with the trachea and esophagus and to plan surgery. Laryngoscopy is indicated in the presence of dysphonia or before surgery in selected patients to document vocal cord mobility and reduce the risk of unrecognized complications. Overall, the diagnostic pathway follows a rational sequence: functional assessment with thyroid-stimulating hormone measurement, ultrasound with risk stratification, scintigraphy when thyroid-stimulating hormone is reduced, fine-needle aspiration when indicated, and integration with additional imaging or specialist assessment in compressive or complex cases.
By definition, benign thyroid tumors are not classified using oncological staging systems such as tumor-node-metastasis staging because they do not possess metastatic potential and do not require classification according to distant neoplastic spread. Nevertheless, systematic assessment of local extension and clinical risk is essential in determining whether and when treatment is required, since nodule volume, compressive effects, and functional autonomy may cause significant morbidity despite the absence of malignancy.
Local extension is assessed mainly through clinical examination and ultrasound. Ultrasound allows accurate measurement of the lesion and definition of its anatomical relationships with the thyroid capsule and adjacent structures, while also identifying cystic, hemorrhagic, or degenerative components that may explain variations in volume and acute symptoms. In patients with large goiters or suspected retrosternal extension, cross-sectional imaging defines tracheal compression, airway deviation, and the degree of mediastinal displacement, providing information that is essential for surgical planning and anesthesiological assessment.
Clinical risk comprises three dimensions. The first is compressive risk, associated with dysphagia, dyspnea, cough, and positional symptoms, which increases with lesion size and location, particularly in retrosternal goiters. The second is functional risk, associated with subclinical or overt hyperthyroidism in autonomous nodules, with potential cardiovascular and skeletal complications that often make definitive treatment appropriate. The third dimension is procedural risk, which considers the feasibility and safety of therapeutic options, including surgery and ablative techniques, in relation to nodule location, vascularity, proximity to the recurrent laryngeal nerve, and size.
The prognosis is generally excellent. In benign nodules monitored over time, the natural history may include slow growth, stability, or fluctuations in volume, particularly when cystic or hemorrhagic components are present, without necessarily indicating malignant transformation. After treatment, prognosis depends mainly on symptom control, normalization of thyroid function in autonomous nodules, and the absence of procedural sequelae. Clinically significant recurrence after complete resection of an adenoma is uncommon, whereas patients with multinodular disease may develop new nodules in the remaining thyroid parenchyma and require proportionate monitoring.
In practical terms, risk assessment in benign thyroid tumors is not a staging process but a clinically oriented stratification intended to guide decision-making: surveillance when the lesion is stable and has a low clinical impact, and treatment when it causes symptoms or functional autonomy, or when the diagnostic pathway cannot provide a reliable characterization without intervention. With an evidence-based, guideline-directed approach, long-term outcomes are favorable in the great majority of patients.
The treatment of benign thyroid tumors is guided by symptoms, function, size, ultrasound characteristics, and the degree of diagnostic certainty. Since most thyroid nodules are benign and many are asymptomatic, the most common option is a conservative strategy based on clinical and ultrasound observation, avoiding unnecessary interventions. Treatment becomes appropriate when the lesion causes compression, clinically significant cosmetic concerns, hyperthyroidism resulting from functional autonomy, or when the diagnosis remains uncertain despite an appropriate diagnostic pathway.
In nodules with benign cytology and a nonsuspicious ultrasound profile, active surveillance is the preferred strategy. Follow-up is intended to detect clinically meaningful changes in ultrasound appearance or the onset of symptoms rather than volume growth alone. Suppressive therapy with levothyroxine is not routinely recommended for nodule reduction because of its limited efficacy and the risk of iatrogenic thyrotoxicosis, particularly in patients with cardiovascular risk factors.
Surgery is indicated in patients with compressive symptoms, large goiters, retrosternal extension, or indeterminate fine-needle aspiration findings associated with a clinically relevant risk of a follicular neoplasm that cannot be characterized without histological examination. The procedure may consist of lobectomy or thyroidectomy according to the distribution of nodules, thyroid function, and clinical preferences. In autonomous nodules, surgery is a definitive option that is particularly useful when compression, multiple nodules, or contraindications to radioactive iodine are present. The aim is to relieve symptoms and correct thyroid dysfunction while preserving residual thyroid function whenever possible, although postoperative hypothyroidism may require replacement therapy.
A well-established treatment for autonomous nodules is radioactive iodine therapy, which is intended to reduce the functional activity of autonomous tissue and control hyperthyroidism. The choice between radioactive iodine and surgery depends on age, comorbidities, gland volume, the degree of autonomy, and patient preferences. Medical management with antithyroid medications may be used as a bridging strategy or in selected circumstances, but it generally does not provide a definitive solution for nodular autonomy.
In recent years, image-guided minimally invasive techniques have acquired an increasing role in selected patients with benign nodules. Ethanol ablation is particularly useful for symptomatic cystic or predominantly cystic nodules. Thermal ablation techniques, such as radiofrequency and laser ablation, may be used for benign solid nodules that cause symptoms or cosmetic concerns, especially when surgery is to be avoided and the lesion has been adequately characterized as benign. European guidelines have defined indications, selection criteria, and safety requirements for these procedures, including the need for a reliable diagnosis of benignity and treatment in a center with appropriate expertise.
Treatment must include risk assessment and an informed discussion of the available alternatives. In benign nodules, the objective is not oncological but functional and symptomatic: to reduce volume when necessary, relieve compression, correct hyperthyroidism in autonomous lesions, and maintain the best possible quality of life. The appropriate choice is often the most proportionate one and requires integration of clinical findings, imaging, and patient preferences.
Follow-up after treatment of a benign thyroid tumor has three main objectives: to confirm the resolution of symptoms, monitor thyroid function, and identify complications or clinically significant nodule regrowth. The intensity of monitoring depends on the type of treatment, the extent of nodular disease, and the clinical risk profile, using a personalized approach that avoids excessive surveillance in stable conditions.
After surgery, the first focus of follow-up is thyroid function. Patients who have undergone lobectomy are assessed for the development of hypothyroidism and the need for replacement therapy, whereas replacement therapy is generally required after thyroidectomy and is adjusted according to thyroid-stimulating hormone levels and the clinical condition. Respiratory and swallowing symptoms that led to surgery are also monitored to verify functional recovery and identify persistent compressive symptoms after treatment of very large goiters.
In patients with autonomous nodules treated with radioactive iodine, follow-up includes confirmation that thyroid function has normalized and identification of post-treatment hypothyroidism, which may develop over time. Clinical monitoring of thyrotoxic symptoms is also performed, together with cardiovascular assessment when indicated in patients with arrhythmias or cardiovascular risk factors. Ultrasound may be used selectively to document volume reduction, but functional stabilization remains the main priority.
After minimally invasive ablation, ultrasound follow-up documents volume reduction and remodeling of the treated area. Volume reduction is progressive and may continue for several months, which is why follow-up examinations should be scheduled according to the expected response kinetics. In autonomous nodules treated with thermal ablation, hormonal assessment is essential in addition to ultrasound to determine the degree of control of functional autonomy and whether further intervention is required.
Surveillance must be proportionate in patients managed conservatively. A nodule with benign cytology and a low-risk ultrasound profile may be monitored at longer intervals, whereas nodules with an intermediate-risk profile or a previously suboptimal specimen require closer monitoring or repeat fine-needle aspiration if discordant findings emerge. The onset of symptoms, changes in thyroid function, or alterations in ultrasound appearance are the events that require complete reassessment.
Overall, post-treatment follow-up in benign thyroid tumors is intended to ensure long-term clinical and functional stability, reduce the risk of sequelae, and maintain an appropriate balance between safety and the judicious use of diagnostic investigations.
Long-term quality of life in patients with benign thyroid tumors depends primarily on the effect of symptoms before treatment, the selected therapeutic approach, and functional sequelae. Since these conditions are generally compatible with a normal life expectancy, the central objective is to preserve well-being, function, and perceived health, avoiding both clinical inertia in the presence of significant symptoms and overtreatment of nodules with a low clinical impact.
In patients with large nodules, improvement in quality of life is often related to the resolution of dysphagia, dyspnea, and cervical discomfort. Cosmetic concerns alone may also have a considerable impact, influencing social relationships and self-esteem, and the volume reduction obtained through surgery or ablation may provide substantial subjective benefit. Assessment must take individual needs into account because tolerance of an enlarged neck varies considerably among patients.
Stability of thyroid function is a major determinant. In autonomous nodules, control of hyperthyroidism improves neurovegetative symptoms and reduces the risk of cardiovascular and skeletal complications, with direct benefits for energy levels, sleep, and ability to work. After definitive treatment, the possible development of hypothyroidism requires levothyroxine replacement therapy and a period of dose adjustment that, when appropriately managed, allows good quality of life to be maintained. Conversely, suboptimal control of thyroid-stimulating hormone levels may be associated with fatigue, weight changes, and reduced performance.
Voice and swallowing are particularly sensitive domains, especially after surgery. Even when major complications are absent, some patients report subtle changes in voice, vocal fatigue, or local sensations that may persist for weeks or months. Early recognition and rehabilitative support, when required, improve outcomes. Similarly, after minimally invasive procedures, local pain and a foreign-body sensation are generally transient but should be managed through appropriate information and follow-up.
Psychological well-being is often affected by the initial diagnostic uncertainty. Communicating the low level of risk and explaining the rationale for surveillance, when selected, reduce anxiety and excessive medicalization. In patients with indeterminate nodules, the pathway toward a histological diagnosis may be a source of stress. A structured approach that clearly explains objectives, alternatives, and functional implications helps patients maintain control over their care pathway.
In the long term, optimal quality of life results from proportionate care: surveillance when safe, intervention when useful, and less invasive techniques when appropriate, with continuous attention to thyroid function and the dimensions of perceived well-being, which in benign tumors are often more important than any oncological outcome.
Complications of benign thyroid tumors arise primarily from mass effect, hormonal dysfunction in autonomous lesions, and treatment-related adverse events. Although biologically benign, a large nodule or multinodular goiter may cause tracheal and esophageal compression, leading to dyspnea and dysphagia, particularly in the presence of retrosternal extension. In selected cases, intranodular hemorrhage may cause an acute increase in volume and pain, with sudden worsening of compressive symptoms.
In autonomous nodules, the most clinically relevant complication is subclinical or overt hyperthyroidism, which increases the risk of atrial fibrillation, heart failure in predisposed individuals, and loss of bone mineral density. These complications do not depend on malignancy but on the persistence and duration of thyrotoxicosis, which is why accurate identification of functional autonomy and definitive treatment when indicated are essential for the primary prevention of systemic sequelae.
Procedural complications depend on the selected therapeutic strategy. After surgery, risks include cervical hematoma, infection, transient or permanent hypocalcemia caused by parathyroid involvement, and recurrent laryngeal nerve injury leading to dysphonia. Even in the absence of permanent nerve injury, transient voice disturbances and cervical discomfort may occur. Hypothyroidism is expected after total thyroidectomy and may also occur after lobectomy, requiring replacement therapy and long-term monitoring.
After radioactive iodine, the main long-term complication is hypothyroidism, which may develop progressively and requires hormonal follow-up. In minimally invasive ablative procedures, the most concerning complications include thermal injury to the recurrent laryngeal nerve with dysphonia, skin burns, hemorrhage, and pain, whereas events such as hypothyroidism are less frequent but remain possible depending on the extent of treatment and the volume of residual thyroid tissue. Accurate patient selection and performance of the procedure in experienced centers significantly reduce the likelihood of clinically relevant adverse events.
Overall, the management of complications in benign thyroid tumors is based on prevention and proportionality: early recognition of compression and functional autonomy, selection of the most appropriate intervention for the clinical profile, use of safe techniques, and follow-up focused on thyroid function and symptoms. Under these conditions, most patients maintain an excellent long-term quality of life.